ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock Fundamental Analysis
USA - NASDAQ:ORTX - US68570P2002 - ADR
16.7 USD
+0.05 (+0.3%)
We assign a fundamental rating of 3 out of 10 to ORTX. ORTX was compared to 534 industry peers in the Biotechnology industry. ORTX has a bad profitability rating. Also its financial health evaluation is rather negative. ORTX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
ORTX had negative earnings in the past year.
In the past year ORTX has reported a negative cash flow from operations.
ORTX had negative earnings in each of the past 5 years.
ORTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ORTX's Return On Assets of -36.05% is fine compared to the rest of the industry. ORTX outperforms 64.76% of its industry peers.
Looking at the Return On Equity, with a value of -90.81%, ORTX is in line with its industry, outperforming 44.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| ROIC | N/A |
ROA(3y)-55.93%
ROA(5y)-54.34%
ROE(3y)-102.43%
ROE(5y)-87.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 69.19%, ORTX belongs to the top of the industry, outperforming 82.97% of the companies in the same industry.
In the last couple of years the Gross Margin of ORTX has remained more or less at the same level.
ORTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ORTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORTX has been increased compared to 1 year ago.
The debt/assets ratio for ORTX is higher compared to a year ago.
2.2 Solvency
ORTX has an Altman-Z score of -5.75. This is a bad value and indicates that ORTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.75, ORTX is not doing good in the industry: 69.31% of the companies in the same industry are doing better.
ORTX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
ORTX has a worse Debt to Equity ratio (0.20) than 69.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.75 |
ROIC/WACCN/A
WACC8.34%
2.3 Liquidity
ORTX has a Current Ratio of 3.12. This indicates that ORTX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.12, ORTX is not doing good in the industry: 67.62% of the companies in the same industry are doing better.
A Quick Ratio of 2.98 indicates that ORTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.98, ORTX is doing worse than 67.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
ORTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.01%, which is quite impressive.
ORTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.23%.
ORTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 108.22% yearly.
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5YN/A
Sales Q2Q%9%
3.2 Future
Based on estimates for the next years, ORTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.90% on average per year.
Based on estimates for the next years, ORTX will show a very strong growth in Revenue. The Revenue will grow by 54.70% on average per year.
EPS Next Y74.37%
EPS Next 2Y32.68%
EPS Next 3Y25.41%
EPS Next 5Y14.9%
Revenue Next Year24%
Revenue Next 2Y58.1%
Revenue Next 3Y63.4%
Revenue Next 5Y54.7%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ORTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ORTX's earnings are expected to grow with 25.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.68%
EPS Next 3Y25.41%
5. Dividend
5.1 Amount
No dividends for ORTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ORTX (1/23/2024, 8:00:02 PM)
16.7
+0.05 (+0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.41%
Ins Owner Change0%
Market Cap380.11M
Revenue(TTM)21.84M
Net Income(TTM)-72920000
Analysts45.71
Price Target16.32 (-2.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.67%
Min EPS beat(2)-96.08%
Max EPS beat(2)50.75%
EPS beat(4)3
Avg EPS beat(4)14.05%
Min EPS beat(4)-96.08%
Max EPS beat(4)72.21%
EPS beat(8)3
Avg EPS beat(8)-8.59%
EPS beat(12)6
Avg EPS beat(12)-4.49%
EPS beat(16)8
Avg EPS beat(16)-0.59%
Revenue beat(2)1
Avg Revenue beat(2)-6.14%
Min Revenue beat(2)-21.69%
Max Revenue beat(2)9.41%
Revenue beat(4)2
Avg Revenue beat(4)-15.77%
Min Revenue beat(4)-79.77%
Max Revenue beat(4)28.97%
Revenue beat(8)6
Avg Revenue beat(8)10.15%
Revenue beat(12)6
Avg Revenue beat(12)-24.54%
Revenue beat(16)8
Avg Revenue beat(16)90.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-85.82%
EPS NQ rev (3m)-85.82%
EPS NY rev (1m)-75.68%
EPS NY rev (3m)-75.68%
Revenue NQ rev (1m)12.87%
Revenue NQ rev (3m)12.87%
Revenue NY rev (1m)6.57%
Revenue NY rev (3m)6.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 17.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.73 | ||
| P/tB | 4.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.1
OCFYN/A
SpS0.96
BVpS3.53
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM | N/A |
ROA(3y)-55.93%
ROA(5y)-54.34%
ROE(3y)-102.43%
ROE(5y)-87.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40.82% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z | -5.75 |
F-Score3
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)157.32%
Cap/Depr(5y)213.58%
Cap/Sales(3y)90.43%
Cap/Sales(5y)127.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
EPS Next Y74.37%
EPS Next 2Y32.68%
EPS Next 3Y25.41%
EPS Next 5Y14.9%
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5YN/A
Sales Q2Q%9%
Revenue Next Year24%
Revenue Next 2Y58.1%
Revenue Next 3Y63.4%
Revenue Next 5Y54.7%
EBIT growth 1Y21.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.86%
OCF growth 3YN/A
OCF growth 5YN/A
ORCHARD THERAPEUTICS PLC-ADR / ORTX FAQ
Can you provide the ChartMill fundamental rating for ORCHARD THERAPEUTICS PLC-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to ORTX.
Can you provide the valuation status for ORCHARD THERAPEUTICS PLC-ADR?
ChartMill assigns a valuation rating of 1 / 10 to ORCHARD THERAPEUTICS PLC-ADR (ORTX). This can be considered as Overvalued.
What is the profitability of ORTX stock?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) has a profitability rating of 2 / 10.
Can you provide the financial health for ORTX stock?
The financial health rating of ORCHARD THERAPEUTICS PLC-ADR (ORTX) is 2 / 10.
Can you provide the expected EPS growth for ORTX stock?
The Earnings per Share (EPS) of ORCHARD THERAPEUTICS PLC-ADR (ORTX) is expected to grow by 74.37% in the next year.